This inventor holds 1 USPTO granted patent. Top assignee: Biomea Fusion, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Innovations of Satish Goud Pappali in GLP-1R Agonists
Introduction
Satish Goud Pappali is an accomplished inventor based in Sunnyvale, CA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that activate GLP-1R pathways. His work is crucial in addressing health issues such as diabetes and obesity.
Latest Patents
Pappali holds a patent for "Heterocyclic GLP-1R agonists." This patent discloses heterocyclic compounds that activate GLP-1R pathways. It also includes pharmaceutical compositions that incorporate these compounds. The methods of using the GLP-1R agonists are outlined for treatment, either alone or in combination with other therapeutic agents, for various diseases or conditions dependent on GLP-1R pathways. He has 1 patent to his name.
Career Highlights
Pappali is currently associated with Biomea Fusion, Inc., where he continues to innovate in the pharmaceutical sector. His expertise in GLP-1R pathways positions him as a key player in the development of new therapeutic solutions.
Conclusion
Satish Goud Pappali's work in the field of GLP-1R agonists showcases his dedication to advancing medical science. His contributions are vital for the treatment of significant health conditions, and his innovative spirit continues to drive progress in the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile